Abstract
Site-directed antibodies which modulate conformation of β-amyloid peptide became the theoretical basis of the immunological approach for treatment of Alzheimers disease (AD). Indeed, antibodies towards the EFRH sequence, located between amino acids 3-6 of the N-terminal region of Alzheimers AβP, found to be a key position in protein conformation modulation, suppress formation of β-amyloid and dissolve already formed fibrillar amyloid. The performance of anti-β-amyloid antibodies in transgenic mice models of AD showed they are delivered to the central nervous system (CNS), preventing and dissolving β-amyloid plaques. Moreover, these antibodies protected the mice from learning and age-related memory deficits. Naturally occurring anti-AβP antibodies have been found in human CSF and in the plasma of healthy individuals, but were significantly lower in AD patients, suggesting that AD may be an immunodeficient disorder. Active and / or passive immunization against β-amyloid peptide has been proposed as a method for preventing and / or treating Alzheimers disease. Experimental active immunization with Aβ 1-42 in humans was stopped in phase II clinical trials due to unexpected neuroinflammatory manifestations. Antibodies generated with this first-generation vaccine might not have the desired therapeutic properties to target the ‘;correct’; mechanism, however, new clinical approaches are now under consideration. Immunotherapy represents fascinating ways to test the amyloid hypothesis and offers genuine opportunities for AD treatment, but requires careful antigen and antibody selection to maximize efficacy and minimize adverse events.
Keywords: alzheimer disease, monoclonal antibodies, abp, immunotherapy, n-terminal region, amyloid plaque, immunodeficiency, neuroinflammation
Current Alzheimer Research
Title: Alzheimers Disease and Immunotherapy
Volume: 1 Issue: 3
Author(s): Beka Solomon
Affiliation:
Keywords: alzheimer disease, monoclonal antibodies, abp, immunotherapy, n-terminal region, amyloid plaque, immunodeficiency, neuroinflammation
Abstract: Site-directed antibodies which modulate conformation of β-amyloid peptide became the theoretical basis of the immunological approach for treatment of Alzheimers disease (AD). Indeed, antibodies towards the EFRH sequence, located between amino acids 3-6 of the N-terminal region of Alzheimers AβP, found to be a key position in protein conformation modulation, suppress formation of β-amyloid and dissolve already formed fibrillar amyloid. The performance of anti-β-amyloid antibodies in transgenic mice models of AD showed they are delivered to the central nervous system (CNS), preventing and dissolving β-amyloid plaques. Moreover, these antibodies protected the mice from learning and age-related memory deficits. Naturally occurring anti-AβP antibodies have been found in human CSF and in the plasma of healthy individuals, but were significantly lower in AD patients, suggesting that AD may be an immunodeficient disorder. Active and / or passive immunization against β-amyloid peptide has been proposed as a method for preventing and / or treating Alzheimers disease. Experimental active immunization with Aβ 1-42 in humans was stopped in phase II clinical trials due to unexpected neuroinflammatory manifestations. Antibodies generated with this first-generation vaccine might not have the desired therapeutic properties to target the ‘;correct’; mechanism, however, new clinical approaches are now under consideration. Immunotherapy represents fascinating ways to test the amyloid hypothesis and offers genuine opportunities for AD treatment, but requires careful antigen and antibody selection to maximize efficacy and minimize adverse events.
Export Options
About this article
Cite this article as:
Solomon Beka, Alzheimers Disease and Immunotherapy, Current Alzheimer Research 2004; 1 (3) . https://dx.doi.org/10.2174/1567205043332126
DOI https://dx.doi.org/10.2174/1567205043332126 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Psychotropic Drugs on the Regulation of Glucose Metabolism
Current Diabetes Reviews Cognitive Impairment in the Septic Brain
Current Neurovascular Research Detection of Mild Cognitive Impairment Based on Virtual Reality: A Scoping Review
Current Alzheimer Research Editorial
Current Medical Imaging Association between ALDH2 Gene Polymorphism and Late-onset Alzheimer Disease: An Up-to-date Meta-analysis
Current Alzheimer Research Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Cognitive Reserve in Aging
Current Alzheimer Research Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology Editorial: Current and Emerging Therapeutics in AD
Current Alzheimer Research The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Serum Cytokine Profile in Alzheimer's Disease Patients After Ingestion of an Antioxidant Beverage
CNS & Neurological Disorders - Drug Targets Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Metal-Score as a Potential Non-Invasive Diagnostic Test for Alzheimer’s Disease
Current Alzheimer Research Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease
Current Alzheimer Research Nanotechnology Based Delivery Systems of Drugs Currently Used to Treat Alzheimer’s Disease
Nanoscience & Nanotechnology-Asia Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy